splicing

Branaplam (LMI 070) is a highly potent, selective and orally active small molecule SMN2 splicing modulator.

CD33 splicing modulator 1 (Compound 1) is a CD33 splicing modulator that targets the CD33 Siglec 3 myeloid cell surface receptor, known for regulating microglial cell activity, and holds potential for studying neurodegenerative diseases such as Alzheimer's disease.

RNA Splicing Modulator 1 (Compound 233) is a modulator of RNA splicing, exhibiting an AC50 value of less than 100 nM [1].

RNA splicing modulator 2 (compound 256) is an RNA splicing modulator [1].

RNA Splicing Modulator 3 (Compound 236) is an effective RNA splicing modulator, exhibiting an AC50 value of less than 100 nM [1].

CD33 Splicing Modulator 1 Hydrochloride (Compound 1) is a myeloid lineage cell surface receptor CD33 Siglec 3 modulator involved in regulating microglia activity. This compound promotes exon 2 skipping in cellular mRNA pools and has research potential in addressing neurodegenerative diseases, including Alzheimer's disease [1].

Risdiplam (RG7916) is a centrally and peripherally distributed and orally administrable small molecule SMN2 pre-mRNA splicing modifier that increases survival motor neuron (SMN) protein levels.

SMN-C3 (MV8T2MCK57) is an orally active modulator of SMN2 splicing, and has the potential to treat spinal muscular atrophy (SMA).

B I09, an IRE-1 RNase inhibitor with an IC50 of 1230 nM, inhibits splicing of XBP1 mRNA in human WaC3 cells and expression of xbp-1 in LPS-stimulated B cells. B I09 can be used to simulate the defects of XBP-1 in CLL cells., an IRE-1 RNase inhibitor with an IC50 of 1230 nM, inhibits splicing of XBP1 mRNA in human WaC3 cells and expression of xbp-1 in LPS-stimulated B cells. B I09 can be used to simulate the defects of XBP-1 in CLL cells., an IRE-1 RNase inhibitor with an IC50 of 1230 nM, inhibits splicing of XBP1 mRNA in human WaC3 cells and expression of xbp-1 in LPS-stimulated B cells. B I09 can be used to simulate the defects of XBP-1 in CLL cells.

CLK1 2-IN-3 (Cpd-3) is a potent and selective CLK1 and CLK2 inhibitor with antiproliferative activity and inhibits the activities of CLK1, CLK2, SRPK1, SRPK2, and SRPK3.CLK1 2-IN-3 induces nuclear speckle enlargement, which induces S6K pre-mRNA-selective splicing and subsequent inhibition of cell growth of multiple cancer cell types. cancer cell types cell growth.

HTT-D3 is an orally active, highly efficient Huntington splicing modulator. It induces HTT mRNA degradation, reduces HTT protein levels, and inhibits P-glycoprotein (P-gp) efflux. This compound can be used in Huntington's disease research.

SMN-C2 is a selective regulator of SMN2 gene splicing, a risdiplam analogue, a selective RNA-binding ligand that regulates pre-mRNA splicing and acts by binding to SMN2 pre-mRNA.SMN-C2 has the potential to be used in the study of spinal muscular atrophy (SMA).

Pladienolide B is a potent spliceosome inhibitor, a macrolide isolated from Streptomyces obtusususus Mer-12, which targets the SF3B1 subunit of the spliceosome.Pladienolide B exerts its antitumor effects by inhibiting pre-mRNA splicing and inducing necrosis.Pladienolide B possesses antitumor activity and can be used to study leukemia and lymphoid tumors. Pladienolide B has antitumor activity and can be used to study leukemia and lymphoid tumors.

Hinokiflavone, a novel modulator of pre-mRNA splicing activity both in vitro and in cellulo, inhibits the assembly of the spliceosome, particularly blocking the formation of the B complex. Additionally, it acts as a SUMO protease inhibitor by impeding the activity of sentrin-specific protease 1 (SENP1). Hinokiflavone also demonstrates significant cytotoxicity, including the inhibition of MMP-9.

1. ISOGINKGETIN (4',4'''-Dimethylamentoflavone), a compound derived from the leaves of Ginkgo biloba, to up-regulate adiponectin secretion with potency comparable to that of rosiglitazone, a known modulator of adiponectin production. 2. Isoginkgetin has anti-tumor activity, the mechanistic basis is splicing inhibition , thus, pre-mRNA splicing inhibitors may represent a novel avenue for development of new anti-cancer agents.3. Isoginkgetin can inhibit tumor cell invasion by regulating phosphatidylinositol 3-kinase Akt-dependent matrix metalloproteinase-9 expression. 4. Isoginkgetin (0.3mg kg ip for 3d) can reduce the level of O2·- in plasma and erythroeyte and sometimes increase the activity of SOD in anoxic rats, the action being stronger than aspirin.

FKBP12 PROTAC dTAG-13 is a PROTAC and selective degrader that can be used for target validation during drug discovery by splicing FKBP12 F36V with CRBN and thereby degrading FKBP12 F36V.

RG7800 hydrochloride is an orally active modulator of SMN2 splicing.

RG7800 (RO6885247) has the potential for spinal muscular atrophy treatment. RG7800 is an SMN2 splicing modifier.

Homocarbonyltopsentin is a small-molecule TSL2-binding compound, binds to pentaloop conformations of TSL2 and promotes a shift to triloop conformations that display enhanced SMN2 exon 7 (E7) splicing (EC50: 16 μM).

N-Palmitoyl phenylalanine is an N-acylamide compound combining the long-chain saturated fatty acid palmitic acid with the essential amino acid L-phenylalanine through an amide bond. In nuclear extracts of HeLa cells, this compound inhibits pre-mRNA splicing activity (IC50 = ~150 µM); however, it does not exhibit splicing activity in whole HeLa cells.

Tuberactinomycin compounds are essential components in the current combination of drugs used to combat Mycobacterium tuberculosis infections. These compounds target bacterial ribosomes and function by binding RNA and disrupting bacterial protein biosynthesis. Tuberactinomycin is produced by the actinomycete [Streptomyces puniceus], which binds RNA and inhibits protein synthesis in prokaryotes as well as certain forms of RNA splicing.

(3S,17S)-FD-895 is an analogue of FD-895. It inhibits the growth of HCT116 cells and shows splicing-modulating activity. This compound can be utilized in cancer research.

VPC-80051 is an hnRNP A1 splicing activity inhibitor that directly interacts with the hnRNP A1 RBD and reduces AR-V7 messenger levels in the 22Rv1 CRPC cell line. VPC-80051 is applicable in prostate cancer research.

3’-Me Meayamycin D is a splice modulator that targets SF3B1 and PHF5A, affecting the pre-mRNA splicing process and downregulating MCL-1 expression. It inhibits the proliferation of cancer cell lines HCT116, SW48, A549, DMS53, and DMS114, with a GI50 range of 4.6-7.2 nM. In mice, it demonstrates good plasma stability with a half-life of 16 hours.